Skip to main content

Talk Bio

Search This Blog

Converting nonresponder insights into smarter drug development strategies in immunology

on June 18, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Better biomarker analysis and mechanistic trials can help convert nonresponder insights into smarter immunology drug development, improving patient selection and targeting underserved groups. 1

Deep, iterative clinical trials that prospectively study responders vs nonresponders—using tissue, multi-omics, and early human data—can reveal why therapies fail and identify new targets or combinations. 1 6 15

Industry and academia are increasingly using AI and large immune atlases to map immune states and compare responders with nonresponders, thereby guiding indications, dosing, and trial design. 4 7 14

Analytical frameworks and trial designs that explicitly incorporate nonresponder data (e.g., PRIME, cell-centered meta‑analyses) can improve power, efficiency, and target identification in immunology and immuno‑oncology. 2 8 15

Sources:

1. ('https://www.biospace.com/drug-development/opinion-converting-nonresponder-insights-into-smarter-drug-development-strategies-in-immunology', 'Convert nonresponder insights into smarter drug development ...')

2. ('https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8694', 'Design for immuno‐oncology clinical trials enrolling both responders and nonresponders')

4. ('https://www.agilisium.com/podcast/decoding-the-immune-system-to-optimize-immunotherapies', 'Dr. Noam Solomon - Pioneering Immunotherapy with AI')

6. ('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198282/', 'Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis')

7. ('https://news.mit.edu/2024/immunai-improving-drug-development-with-immune-system-map-0411', 'Improving drug development with a vast map of the ...')

8. ('https://gut.bmj.com/content/68/4/604', 'Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD')

14. ('https://nimml.org/news/detail/applying-artificial-intelligence-to-improve-drug-development', 'Applying Artificial Intelligence to Improve Drug Development')

15. ('https://pmc.ncbi.nlm.nih.gov/articles/PMC10802741/', 'Immune and molecular landscape behind non-response to ...')

Biological Markers Clinical Trials immune mapping immunology drug development mechanistic trials nonresponder

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC